Hubungan Kepatuhan Penggunaan Obat dengan Kualitas Hidup Pasien Skizofrenia Hebefrenik Rawat Jalan di Poliklinik Jiwa RSUD R. Syamsudin, S.H. Kota Sukabumi
DOI:
https://doi.org/10.29313/bcsp.v3i2.8675Keywords:
Skizofrenia hebefrenik, kepatuhan penggunaan obat, kualitas hidup.Abstract
Abstract. Schizophrenia is a mental illness with symptoms of psychosis and cognitive dysfunction. The prevalence of schizophrenia in Indonesia is 400,000 people. Non-adherence to antipsychotic medication has an impact on leading to disease complication, low effectiveness of drug treatment, and decreased quality of life. This study aims to determine the characteristics of patients, identify the level of medication adherence and the level of quality of life and determine relationship of medication adherence and quality of life. The research instrument used the MMAS-8 to asses medication adherence and WHOQOL-BREF to assess the quality of life and statistical correlation analyzed using the chi-square test. The results showed that relationship of medication adherence and quality of life in patients with hebephrenic schizophrenia at the psychiatric polyclinic RSUD R. Syamsudin, S.H. Sukabumi City had a low level of adherence and quality of life, a correlation analysis showed that there was a significant correlation between medication adherence and quality of life (p value=0.00, P<0.05).
Abstrak. Skizofrenia merupakan salah satu gangguan kesehatan mental dengan gejala psikosis serta disfungsi kognitif. Prevalensi penderita skizofrenia di Indonesia yaitu sebanyak 400.000 orang. Ketidakpatuhan penggunaan obat antipsikotik dapat menimbulkan komplikasi, tujuan terapi tidak tercapai dan menurunkan kualitas hidup pasien. Penelitian ini bertujuan untuk mengetahui karakteristik pasien, mengidentifikasi tingkat kepatuhan penggunaan obat dan tingkat kualitas hidup serta mengetahui hubungan antara kepatuhan penggunaan obat dengan kualitas hidup. Penelitian ini menggunakan kuesioner MMAS-8 untuk menilai kepatuhan penggunaan obat dan WHOQOL-BREF untuk menilai kualitas hidup serta analisis korelasi secara statistik dengan metode chi-square. Dari hasil penelitian yang telah dilakukan hubungan kepatuhan penggunaan obat dengan kualitas hidup pasien skizofrenia hebefrenik rawat jalan di poliklinik jiwa RSUD R. Syamsudin, S.H. Kota Sukabumi menunjukkan tingkat kepatuhan dan tingkat kualitas hidup rendah, serta pada hasil analisis korelasi menunjukkan terdapat hubungan signifikan antara kepatuhan penggunaan obat dan kualitas hidup (p value=0.00, P<0.05).
References
[2] C. H. Lin, F. C. Chen, H. Y. Chan, and C. C. Hsu, “Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics,” Int. J. Neuropsychopharmacol., vol. 22, no. 9, pp. 541–547, 2019, doi: 10.1093/IJNP/PYZ035.
[3] Riskesdas, “Kementerian Kesehatan Republik Indonesia,” Kementeri. Kesehat. RI, vol. 1, no. 1, p. 1, 2019, [Online]. Available: https://www.kemkes.go.id/article/view/19093000001/penyakit-jantung-penyebab-kematian-terbanyak-ke-2-di-indonesia.html.
[4] R. NASIONAL, “Laporan_Nasional_RKD2018_FINAL.pdf,” Badan Penelitian dan Pengembangan Kesehatan. p. 674, 2018, [Online]. Available: http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf.
[5] E. Loots, E. Goossens, T. Vanwesemael, M. Morrens, B. Van Rompaey, and T. Dilles, “Interventions to improve medication adherence in patients with schizophrenia or bipolar disorders: A systematic review and meta-analysis,” Int. J. Environ. Res. Public Health, vol. 18, no. 19, 2021, doi: 10.3390/ijerph181910213.
[6] J. Ishii et al., “Association between functional recovery and medication adherence in schizophrenia,” Neuropsychopharmacol. Reports, vol. 42, no. 4, pp. 510–515, 2022, doi: 10.1002/npr2.12294.
[7] A. R. A. Nalendra et al., Statistika Seri Dasar dengan SPSS. 2021.
[8] G. M. Giordano, P. Bucci, A. Mucci, P. Pezzella, and S. Galderisi, “Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review,” Front. Psychiatry, vol. 12, no. December, pp. 1–10, 2021, doi: 10.3389/fpsyt.2021.789179.
[9] M. Davidson, “Cognitive impairment as a diagnostic criterion and treatment target in schizophrenia,” World Psychiatry, vol. 18, no. 2, pp. 171–172, 2019, doi: 10.1002/wps.20651.
[10] F. J. Charlson et al., “Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016,” Schizophr. Bull., vol. 44, no. 6, pp. 1195–1203, 2018, doi: 10.1093/schbul/sby058.
[11] A. Gogos, A. M. Sbisa, J. Sun, A. Gibbons, M. Udawela, and B. Dean, “A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings,” Int. J. Endocrinol., vol. 2015, 2015, doi: 10.1155/2015/615356.
[12] C. Hakulinen et al., “The association between early-onset schizophrenia with employment, income, education, and cohabitation status: nationwide study with 35 years of follow-up,” Soc. Psychiatry Psychiatr. Epidemiol., vol. 54, no. 11, pp. 1343–1351, 2019, doi: 10.1007/s00127-019-01756-0.
[13] M. Tesli et al., “Educational attainment and mortality in schizophrenia,” Acta Psychiatr. Scand., vol. 145, no. 5, pp. 481–493, 2022, doi: 10.1111/acps.13407.
[14] A. Semahegn, K. Torpey, A. Manu, N. Assefa, G. Tesfaye, and A. Ankomah, “Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis,” Syst. Rev., vol. 9, no. 1, pp. 1–18, 2020, doi: 10.1186/s13643-020-1274-3.
[15] N. Cahaya, S. A. Kristina, A. W. Widayanti, and J. Green, “Interventions to Improve Medication Adherence in People with Schizophrenia: A Systematic Review,” Patient Prefer. Adherence, vol. 16, no. August, pp. 2431–2449, 2022, doi: 10.2147/PPA.S378951.
[16] K. Hahlweg and D. H. Baucom, “Family therapy for persons with schizophrenia: neglected yet important,” Eur. Arch. Psychiatry Clin. Neurosci., vol. 273, no. 4, pp. 819–824, 2022, doi: 10.1007/s00406-022-01393-w.
[17] R. Longa, A. N. Antara, and A. Sumekar, “Hubungan Tingkat Pengetahuan dengan Kepatuhan Minum Obat,” vol. 6, no. 1, 2023.
[18] J. Intharit, K. Kittiwattanagul, W. Chaveepojnkamjorn, and K. Tudpor, “Risk and protective factors of relapse in patients with firstepisode schizophrenia from perspectives of health professionals: a qualitative study in northeastern Thailand [version 1; peer review: awaiting peer review],” F1000Research, vol. 10, pp. 1–15, 2021, doi: 10.12688/f1000research.53317.1.
[19] C. U. Correll and O. D. Howes, “Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options,” J. Clin. Psychiatry, vol. 82, no. 5, 2021, doi: 10.4088/JCP.MY20096AH1C.
[20] D. Desalegn, S. Girma, and T. Abdeta, “Quality of life and its association with psychiatric symptoms and socio-demographic characteristics among people with schizophrenia: A hospital-based cross-sectional study,” PLoS One, vol. 15, no. 2, pp. 1–15, 2020, doi: 10.1371/journal.pone.0229514.
[21] A. Joshi et al., “Quality of life in Schizophrenia patients with and without adequate pharmaceutical care: A randomized controlled study,” Clin. Epidemiol. Glob. Heal., vol. 20, no. August 2022, p. 101208, 2023, doi: 10.1016/j.cegh.2022.101208.
[22] S. Coaccioli, P. Sarzi-Puttini, P. Zis, G. Rinonapoli, and G. Varrassi, “Osteoarthritis: New Insight on Its Pathophysiology,” J. Clin. Med., vol. 11, no. 20, pp. 1–12, 2022, doi: 10.3390/jcm11206013.
[23] C. Domenech et al., “Correlation of health-related quality of life in clinically stable outpatients with schizophrenia,” Neuropsychiatr. Dis. Treat., vol. 15, pp. 3475–3486, 2019, doi: 10.2147/NDT.S218578.
[24] M. Beaudoin, A. Hudon, C. E. Giguère, S. Potvin, and A. Dumais, “Prediction of quality of life in schizophrenia using machine learning models on data from Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial,” Schizophrenia, vol. 8, no. 1, pp. 1–9, 2022, doi: 10.1038/s41537-022-00236-w.
[25] D. Desalegn, S. Girma, and T. Abdeta, “Quality of life and its association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in Southwest Ethiopia: A hospital-based cross-sectional study,” Health Qual. Life Outcomes, vol. 18, no. 1, pp. 1–9, 2020, doi: 10.1186/s12955-020-01340-0.
[26] M. Junaid Farrukh, M. Makmor Bakry, E. Hatah, and T. Hui Jan, “Medication adherence status among patients with neurological conditions and its association with quality of life,” Saudi Pharm. J., vol. 29, no. 5, pp. 427–433, 2021, doi: 10.1016/j.jsps.2021.04.003.
[27] W. Yu et al., “Analysis of medication adherence and its influencing factors in patients with schizophrenia in the chinese institutional environment,” Int. J. Environ. Res. Public Health, vol. 18, no. 9, pp. 1–10, 2021, doi: 10.3390/ijerph18094746.
[28] J. Amidos Pardede and J. M. Purba, “Dukungan Keluarga Berhubungan Dengan Kualitas Hidup Pasien Skizofrenia,” J. Ilm. Permas J. Ilm. STIKES Kendal, vol. 10, no. 4, pp. 645–654, 2020, [Online]. Available: https://repository.usu.ac.id/bitstream/handle/123456789/3949/Fulltext.pdf?sequence=1&isAllowed=y.
